Industries - Antiviral Drugs Market Analysis by Drug Class (Reverse Transcriptase Inhibitors, DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), by Type (Generic, Branded), by Application (Hepatitis, HIV, Influenza, Herpes), and by Region – Forecast to 2025

Antiviral Drugs Market Analysis by Drug Class (Reverse Transcriptase Inhibitors, DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), by Type (Generic, Branded), by Application (Hepatitis, HIV, Influenza, Herpes), and by Region – Forecast to 2025
October 2020

SKU: N/A Category:
Clear
  • Description
  • Additional information
  • Enquire about

Description

Antiviral Drugs Market Analysis by Drug Class (Reverse Transcriptase Inhibitors, DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), by Type (Generic, Branded), by Application (Hepatitis, HIV, Influenza, Herpes), and by Region - Forecast to 2025

Published: October 2020 | Historical Data: 2017-2019 | Base Year: 2019
SKU: ICI-HC-1020 | Number of Pages: 148 | Category: Pharmaceuticals

The global antiviral drugs market size is estimated to be USD 55.91 billion in 2019 and is expected to witness a CAGR of 2.5% during the forecast period. Rise in the number of cases of viral infections such as hepatitis, influenza, coronavirus, and human immunodeficiency virus (HIV) is a key driver for global antiviral drugs market growth. Moreover, the increasing clinical trials, rising R&D investment, and government initiatives for availability of advanced drugs with lesser adverse effects are some of the other drivers propelling the market growth. However, stringent regulatory scenario and lack of skilled research professionals are expected to restrain global growth.

Antiviral Drugs Market

By Drug Class

Based on drug class, the market is segmented into reverse transcriptase inhibitors, neuraminidase inhibitors, DNA polymerase inhibitors, protease inhibitors, and others. In 2019, the reverse transcriptase inhibitors segment commanded the maximum revenue share due to increasing R&D initiates by pharmaceutical companies and its ability to slow down the viral infection. This segment is also expected to grow at the fastest CAGR during the forecast period. DNA polymerase inhibitors segment is expected to foresee significant growth during the forecast period.

By Type

Based on type, the market is categorized into generics and branded. In 2019, the branded segment accounted for the maximum revenue share due to rising consumer perception towards high quality branded medicines worldwide. Generic segment is anticipated to grow at fastest CAGR during the forecast period, due to the increasing awareness about benefits of generic medicine among consumers and government initiatives such as funding & investments.

By Applications

Based on application, the market is categorized into hepatitis, HIV, influenza, herpes, and others. Hepatitis application segment accounted for the highest revenue share in 2019 and is projected to maintain its dominance over the forecast period. Hepatitis is of three types A, B, and C and has large availability of antiviral drugs to treat each type of hepatitis. The market is driven by the increasing prevalence and incidences of varied types of hepatitis. Moreover, HIV segment is the fastest growing market for antiviral drugs due to large patient base worldwide.

Regional Insights

In 2019, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the advanced healthcare infrastructure, presence of large number of pharmaceutical & biotechnology firms, and rising awareness initiatives by government. For instance, in the U.S., cutting-edge medical research infrastructure coupled with extensive drug clinical trials are fuelling the growth of antiviral drugs. Asia Pacific is projected to exhibit the fastest CAGR over the forecast period owing to the rising prevalence of viral infections, improving healthcare sector, and rising research & development activities in this region.

North America Antiviral Drugs Market Size (2017-2025), USD Billion

North America Antiviral Drugs Market

Competitor Insights

Some of the major companies in the antiviral drugs market are Bristol Myers Squibb (U.S.), Gilead Sciences, Inc. (U.S.), Cipla Limited (U.S.), F. Hoffmann-La Roche AG (Switzerland), Aurobindo Pharma Limited (India), AbbVie Inc. (U.S.), Dr. Reddy’s Laboratories (India), Merck & Co., Inc. (U.S.), Johnson & Johnson (U.S.), and GlaxoSmithKline plc (U.K.). The leading players have adopted strategic collaborations, mergers & acquisitions, and novel product development as key strategies to capture the market share.

 

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country-level along with key market trends and dynamics from 2017 to 2025. The antiviral drugs market report is categorized into the following segments and subsegments:

Antiviral Drugs Market, By Drug Class (Revenue, 2017-2025, USD Billion)

  • Reverse Transcriptase Inhibitors (RTI)
  • DNA Polymerase Inhibitors (DPI)
  • Neuraminidase Inhibitors (NI)
  • Protease Inhibitors (PI)
  • Others

Antiviral Drugs Market, By Type (Revenue, 2017-2025, USD Billion)

  • Generics
  • Branded

Antiviral Drugs Market, By Application (Revenue, 2017-2025, USD Billion)

  • Hepatitis
  • HIV
  • Influenza
  • Herpes
  • Others

Antiviral Drugs Market, By Region (Revenue, 2017-2025, USD Billion)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Scope of Antiviral Drugs Market Report:

Key Parameters Details
Data Availability 2017-2025
Historical Years 2017-2019
Base Year Considered 2019
Forecast Period 2019-2025
Company Profiles 10
Companies Considered (Across Value Chain) >60
Value Units Value in USD and CAGR in %
Market Segments Drug Class, Type, and Application
Regional Coverage North America (U.S. and Canada), Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe), Asia Pacific (China, Japan, Australia, India, South Korea, Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), and the Middle East & Africa (South Africa, Saudi Arabia, Rest of MEA)
Key Market Players Bristol Myers Squibb (U.S.), Gilead Sciences, Inc. (U.S.), Cipla Limited (U.S.), F. Hoffmann-La Roche AG, (Switzerland), Aurobindo Pharma Limited (India), AbbVie Inc. (U.S.), Dr. Reddy’s Laboratories (India), Merck & Co., Inc. (U.S.), Johnson & Johnson (U.S.), and GlaxoSmithKline plc (U.K.)
Custom Analysis Customization up to 60 analyst hours

Antiviral Drugs Market, By Drug Class (Revenue, 2017-2025, USD Billion)

  • Reverse Transcriptase Inhibitors (RTI)
  • DNA Polymerase Inhibitors (DPI)
  • Neuraminidase Inhibitors (NI)
  • Protease Inhibitors (PI)
  • Others

Antiviral Drugs Market, By Type (Revenue, 2017-2025, USD Billion)

  • Generics
  • Branded

Antiviral Drugs Market, By Application (Revenue, 2017-2025, USD Billion)

  • Hepatitis
  • HIV
  • Influenza
  • Herpes
  • Others

Antiviral Drugs Market, By Region (Revenue, 2017-2025, USD Billion)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA
1. Research Methodology
 1.1. Research Objective
 1.2. Study Scope: Market Segments
 1.3. Study Timeframe, Limitations& Currency
 1.4. Domain-Assisted Cognition (DAC) Framework
  1.4.1. Three-stage Research Methodology
   1.4.1.1. Understand Ecosystem
    1.4.1.1.1. Secondary Research
    1.4.1.1.2. Primary Research
    1.4.1.1.3. Internal Repository
   1.4.1.2. Synthesize Information
    1.4.1.2.1. Data Analysis
    1.4.1.2.2. Data Triangulation
   1.4.1.3. Predict/Project Growth
    1.4.1.3.1. Market Size Estimation
     1.4.1.3.1.1. Bottom-up Approach
     1.4.1.3.1.2. Top-down Approach
    1.4.1.3.2. Data Validation
  1.4.2. Two-stage Quality Check Mechanism
   1.4.2.1. Inspection & Reporting
   1.4.2.2. Quality Audit
2. Market Summary
 2.1. Market Definition & Market Landscape
 2.2. Market Segment Snapshot
 2.3. Geographic Market Snapshot
3. Market Dynamics
 3.1. Market Driver Analysis
  3.1.1. Increasing incidences of viral infection
  3.1.2. Rising research & development activity
  3.1.3. Market expansion by leading players
  3.1.4. Covid-19 Pandemic in 2020
 3.2. Market Restraint Analysis
  3.2.1. Stringent regulatory framework
  3.2.2. Lack of skilled personnel
 3.3. Market Opportunities
  3.3.1. Patent expiration of leading antiviral drugs
  3.3.2. Increasing market penetration in emerging economies
4. Industry Outlook
 4.1. Key Market Trends
 4.2. Value Chain Analysis
 4.3. Porter’s 5 Forces Analysis
 4.4. Pricing Analysis (2017-2019)
 4.5. Product Benchmarking
5. Covid-19 Impact and Deviation Analysis
 5.1. Covid-19 Prevalence Analysis
 5.2. Key Market Trends
 5.3. Market Size Deviation Analysis (2020-2025)
6. Antiviral Drugs Market Size and Forecast, by Drug Class (2017-2025), USD Million
 6.1. Reverse Transcriptase Inhibitors (RTI)
 6.2. DNA Polymerase Inhibitors (DPI)
 6.3. Neuraminidase Inhibitors (NI)
 6.4. Protease Inhibitors (PI)
 6.5. Others
7. Antiviral Drugs Market Size and Forecast, by DrugType (2017-2025), USD Million
 7.1. Branded
 7.2. Generics
8. Antiviral Drugs Market Size and Forecast, by Application (2017-2025), USD Million
 8.1. Hepatitis
 8.2. HIV
 8.3. Influenza
 8.4. Herpes
 8.5. Others
9. Regional Analysis (2017-2025), USD Million
 9.1. North America
  9.1.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
  9.1.2. Market Size & Forecast, by Type (2017-2025), USD Million
  9.1.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.1.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.1.5. U.S.
   9.1.5.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.1.5.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.1.5.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.1.6. Canada
   9.1.6.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.1.6.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.1.6.3. Market Size & Forecast, by Application (2017-2025), USD Million
 9.2. Europe
  9.2.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
  9.2.2. Market Size & Forecast, by Type (2017-2025), USD Million
  9.2.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.2.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.2.5. Germany
   9.2.5.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.5.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.2.5.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.2.6. UK
   9.2.6.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.6.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.2.6.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.2.7. France
   9.2.7.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.7.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.2.7.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.2.8. Spain
   9.2.8.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.8.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.2.8.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.2.9. Italy
   9.2.9.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.9.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.2.9.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.2.10. Russia
   9.2.10.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.10.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.2.10.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.2.11. Rest of Europe
   9.2.11.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.11.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.2.11.3. Market Size & Forecast, by Application (2017-2025), USD Million
 9.3. Asia Pacific (APAC)
  9.3.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
  9.3.2. Market Size & Forecast, by Type (2017-2025), USD Million
  9.3.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.3.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.3.5. China
   9.3.5.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.5.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.3.5.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.3.6. Japan
   9.3.6.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.6.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.3.6.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.3.7. India
   9.3.7.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.7.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.3.7.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.3.8. Australia
   9.3.8.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.8.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.3.8.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.3.9. South Korea
   9.3.9.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.9.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.3.9.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.3.10. Rest of Asia Pacific
   9.3.10.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.10.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.3.10.3. Market Size & Forecast, by Application (2017-2025), USD Million
 9.4. Latin America (LATAM)
  9.4.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
  9.4.2. Market Size & Forecast, by Type (2017-2025), USD Million
  9.4.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.4.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.4.5. Brazil
   9.4.5.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.4.5.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.4.5.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.4.6. Mexico
   9.4.6.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.4.6.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.4.6.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.4.7. Argentina
   9.4.7.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.4.7.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.4.7.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.4.8. Rest of LATAM
   9.4.8.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.4.8.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.4.8.3. Market Size & Forecast, by Application (2017-2025), USD Million
 9.5. Middle East & Africa (MEA)
  9.5.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
  9.5.2. Market Size & Forecast, by Type (2017-2025), USD Million
  9.5.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.5.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.5.5. South Africa
   9.5.5.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.5.5.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.5.5.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.5.6. Saudi Arabia
   9.5.6.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.5.6.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.5.6.3. Market Size & Forecast, by Application (2017-2025), USD Million
  9.5.7. Rest of MEA
   9.5.7.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.5.7.2. Market Size & Forecast, by Type (2017-2025), USD Million
   9.5.7.3. Market Size & Forecast, by Application (2017-2025), USD Million
10. Competitor Analysis
 10.1. Market Player Comparison
 10.2. Product-wise Player Mapping
 10.3. Region-wise Player Mapping
 10.4. Market Share Analysis
 10.5. Market Position Analysis
 10.6. Recent Development Analysis
11. Company Profiles
 11.1. Bristol Myers Squibb (U.S.)
  11.1.1. Company Overview
  11.1.2. Company Financials
  11.1.3. Product Portfolio
  11.1.4. Recent Developments
 11.2. Gilead Sciences, Inc. (U.S.)
  11.2.1. Company Overview
  11.2.2. Company Financials
  11.2.3. Product Portfolio
  11.2.4. Recent Developments
 11.3. Cipla Limited (U.S.)
  11.3.1. Company Overview
  11.3.2. Company Financials
  11.3.3. Product Portfolio
  11.3.4. Recent Developments
 11.4. F. Hoffmann-La Roche AG, (Switzerland)
  11.4.1. Company Overview
  11.4.2. Company Financials
  11.4.3. Product Portfolio
  11.4.4. Recent Developments
 11.5. Aurobindo Pharma Limited (India)
  11.5.1. Company Overview
  11.5.2. Company Financials
  11.5.3. Product Portfolio
  11.5.4. Recent Developments
 11.6. AbbVie Inc. (U.S.)
  11.6.1. Company Overview
  11.6.2. Company Financials
  11.6.3. Product Portfolio
  11.6.4. Recent Developments
 11.7. Dr. Reddy's Laboratories (India)
  11.7.1. Company Overview
  11.7.2. Company Financials
  11.7.3. Product Portfolio
  11.7.4. Recent Developments
 11.8. Merck & Co., Inc. (U.S.)
  11.8.1. Company Overview
  11.8.2. Company Financials
  11.8.3. Product Portfolio
  11.8.4. Recent Developments
 11.9. Johnson & Johnson (U.S.)
  11.9.1. Company Overview
  11.9.2. Company Financials
  11.9.3. Product Portfolio
  11.9.4. Recent Developments
 11.10. GlaxoSmithKline plc (U.K.)
  11.10.1. Company Overview
  11.10.2. Company Financials
  11.10.3. Product Portfolio
  11.10.4. Recent Developments

Key questions addressed by the research report-

  1. What are the current market trends and future market forecast from 2019 to 2025 for antiviral drugs market?
  2. What are the market dynamics and probable opportunities for market players during the forecast period?
  3. Initiatives undertaken my market players to address the COVID-19 impact to sustain in the competitive market.
  4. Which geographies have immense opportunities in different segments of the antiviral drugs market?
  5. What are the recent strategies adopted by market players such as product launch, partnership, agreement, collaboration, merger & acquisition, and geographical expansion?


    Have any question? Check your free sample before purchase or connect with our expert.

    Additional information

    Licensing Types

    , , ,

    Enquire about Antiviral Drugs Market Analysis by Drug Class (Reverse Transcriptase Inhibitors, DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), by Type (Generic, Branded), by Application (Hepatitis, HIV, Influenza, Herpes), and by Region - Forecast to 2025